Report an error   


Submitted: 24 March 2017 Modified: 11 April 2017
HERDIN Record #: PCHRD17032414450182

A pilot study on single nucleotide polymorphisms of cathechol-O-methyltransferase (VAL158MET) and CYP2D6*10 (PRO34SER) and opioid use among cancer pain patients.

1Francis O. Javier,
2Antonio B. Yap,
3Merlina L. Cabrera,
4Lyde A. Magpantay,
5Cynthia A. Mapua,
6Maria Luisa G. Daroy,
7Michael O. Baclig

Abstract

A hospital-based cross-sectional study was conducted to evaluate the association between catechol-0-methyltransferase (COMT) and CYP2D6*10 single nucleotide polymorphisms (SNPs) and opioid consumption among cancer pain patients. COMT and CYP2D6*10 genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). In this study, there was no association noted between COMT genotype and dosage of morphine. The odds of moderate to high morphine use among patients with Val/Val genotype were 1.78 times higher compared to those with Val/Met genotype. For CYP2D6*10 SNPs, there was no association noted when various doses of tramadol were compared against the three CYP2D6*10 genotypes (Homozygous C/C; Heterozygous C/T and Homozygous T/T). In conclusion, there was no association seen in both the pain candidate genes, COMT (Va1158Met) and CYP2D6*10 (Pro34Ser) and opioid use among cancer pain patients.

1.
Publication Type:
Journal
Publication Sub Type:
Journal Article, Original
Title:
St. Luke's Healthcare Journal
Frequency:
Semi-Annual
Publication Date:
July-December 2016
Volume:
11
Issue:
2
Page(s):
55-62
Publisher:
St. Luke's Medical Center

LocationCall NumberAvailable FormatAvailability
Philippine Council for Health Research and Development Library Box No. 35 Fulltext Print Format (Request Document)